LexaGene Holdings Inc. Joins The Stock Day Podcast to Discuss The Commercialization of Their Genetic Analyzers

Phoenix, Arizona--(Newsfile Corp. - November 18, 2019) - The Stock Day Podcast welcomed LexaGene Holdings Inc. (OTCQB: LXXGF) ("the Company"), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. President and Director, Daryl Rebeck, joined Stock Day host Everett Jolly.

Jolly began the interview by asking about the Company's current plans. "We've been building this company out to one of the most exciting points we've ever been at," said Rebeck, noting that the Company has been able to de-risk its assets during beta testing to now shift into the upcoming commercial stage. "We're ramping up sales and development staff, getting to that commercial stage as soon as possible where we're getting it into the hands of customers," added Rebeck when discussing the Company's plans to launch its flagship product the LX Analyzer.

Jolly asked about the Company's monetization strategy. Rebeck shared that the Company is planning for commercialization to occur in Q2 of next year. "We're at that stage now where we'll start taking pre-sales," said Rebeck. "There's so much demand around the product right now," added Rebeck, noting that the product can be developed at an incredibly low cost. "You're going to see profit very quickly as well."

Jolly noted that the Company recently raised C$6.6 million in capital and asked what these funds will be used for. "We're very excited about getting this done," said Rebeck, adding that the funding was made possible by the Company's commercial advancements. "That money really solidifies our pathway to commercialization, and it seals our advancement toward market readiness."

"What do the next twelve months look like for your company?" asked Jolly. Rebeck shared that the next twelve months will be largely focused on the commercialization of their product. "We want this to really be out in the field. We want to be able to penetrate these industries as best as we think we can to meet the demand that is there," said Rebeck.

To close the interview, Rebeck shared that the Company is currently undervalued despite its incredible potential and the high demand for its technology. "I look at this as one of the most exciting entry points we've ever had," closed Rebeck.

To hear Daryl Rebeck's entire interview, follow the link to the podcast here: https://audioboom.com/posts/7425943-lexagene-holdings-inc-joins-the-stock-day-podcast-to-discuss-the-commercialization-of-their-gene


Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/

About LexaGene Holdings Inc.

LexaGene is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press 'go'. The LX Analyzer delivers excellent sensitivity, specificity, and breadth of detection and can process multiple samples at a time, in an on-demand fashion, returning results in about 1 hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.

Investor Relations

Jay Adelaar
Vice President of Capital Markets, LexaGene
800.215.1824 ext 207
jadelaar@lexagene.com

The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors -- including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues -- that could cause actual results to differ materially from the Company's expectations as disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.

SOURCE:

Stock Day Media

602-441-3474

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/49822